What is Trazimera™ (trastuzumab-qyyp)?

Trazimera™ (trastuzumab-qyyp) is an engineered biologic immunotherapy medication that may be used to treat certain women with HER2+ breast cancer (human epidermal growth factor receptor-2-positive). Trazimera is classified as “biosimilar” to Herceptin®1. Biosimilar medications are approved based on the similarity of their action to approved medications.

Trazimera is approved for the treatment of certain patients with HER2+ early breast cancer, metastatic breast cancer, and metastatic gastric cancer or gastroesophageal junction adenocarcinoma. Trazimera is designed to be used after or along with chemotherapy.2

Breast cancer tumors are characterized as HER2+ or HER2- cancers. HER2 refers to a particular protein that appears on the surface of cancer cells and makes the cells multiply faster. When cancer cells produce too many HER2 molecules, they are referred to as HER2+ tumors. HER2- cancers produce few or no HER2 molecules.3 About 15-30% of breast cancers are HER2+.1

What are the ingredients in Trazimera?

The active ingredient in Trazimera is trastuzumab-qyyp.

How does Trazimera work?

Trazimera is one of several engineered monoclonal antibodies used to treat cancer. Our bodies naturally produce antibodies, which are immune factors that act against foreign organisms that invade and threaten our health. Drugmakers have engineered a variety of antibodies to target the mechanisms that cause certain diseases, including breast cancer.

Trazimera is designed to bind to the HER2 molecule, which appears at high levels on the surface of HER2+ breast cancers. HER2 molecules stimulate tumors to grow especially fast. By blocking HER2, Trazimera tamps down the uncontrolled growth of the tumor cells. Since Trazimera works only with tumors that are HER2+, your doctor will test your tumor for HER2 before prescribing this medication.4

What are the possible side effects of Trazimera?

Common side effects with Trazimera include1:

  • Fever
  • Nausea
  • Vomiting
  • Diarrhea
  • Infections
  • Increased cough
  • Headache
  • Feeling tired
  • Shortness of breath
  • Rash
  • Low white and red blood cell counts
  • Muscle pain
  • Infusion reactions

In some patients, Trazimera may cause more harmful, sometimes life-threatening side effects. These include1:

  • Serious heart problems, including congestive heart disease
  • Severe lung problems, including swelling of the lungs
  • Worsening of chemotherapy-induced reductions in white blood cells
  • Severe reaction to infusion, which is how the medication is given

Trazimera has been shown to harm fetuses, so it is important not to become pregnant while you are taking it. Women who can become pregnant who receive Trazimera should use birth control during their treatment and for seven months after treatment with Trazimera is completed (patients should discuss appropriate birth control methods with their doctor). This is not a complete list of all potential side effects of Trazimera. For more information, consult your doctor or healthcare provider. If you notice any new or worsening side effects, contact your doctor or healthcare provider immediately.

Things to note about Trazimera

Before taking Trazimera, tell your doctor about all your health conditions, including if you5:

  • Have or have had heart problems
  • Have or have had lung or breathing problems
  • Are being treated for an infection
  • Are pregnant or plan to become pregnant or are breastfeeding

Before starting treatment with Trazimera, patients should talk to their doctor about all medications (prescription and over-the-counter), vitamins, and herbal supplements they are taking. Some medications or supplements may interfere with each other and may cause side effects. Because Trazimera may cause serious harm to your heart, your doctor will monitor its functioning before and during your treatment.

Receiving Trazimera

Trazimera is given either through a vein in your arm via intravenous (IV) infusion. Infusions of Trizimera must be given in a medical office, and they take about 30-90 minutes to complete.4 Your doctor will determine the appropriate dosing regimen and administration schedule for you. When used as adjuvant therapy, Trazimera is generally given in conjunction with other chemotherapy medications. Other additional treatments, such as chemotherapy, will take additional time for infusion administration when given in combination with Trazimera infusion.

For more information about Trazimera, read the complete prescribing information.

Patients should talk to their doctor if they have any questions, or if they have questions regarding their Trazimera regimen.

By providing your email address, you are agreeing to our privacy policy. We never sell or share your email address.

Written by: Editorial Team | Last reviewed: October 2020.